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Abstract Article Info 
Introduction: Indonesia are among the top 5 countries with highest prevalence of NPC with a meta-analysis 
from 2018 stating prevalence as high as 13.084 cases. According to the latest guideline published by National 
Comprehensive Cancer Network (NCCN) in 2018. The main treatment for NPC remain radiotherapy, 
chemotherapy, and surgery. Induction or adjuvant chemotherapy place in treatment are still uncertain because 
variety of results from multiple clinical trial. 
Discussion: This review evaluates the current outcome of patient undergoing chemoradiotherapy with or 
without adjuvant chemotherapy and its usage in nasopharyngeal carcinoma patient. Search on online databases 
are performed with keywords including “nasopharyngeal carcinoma”, “chemotherapy”, “adjuvant” and 
“outcome” along with their synonyms. Studies in English from 2014-2019 are included.  Quality assessment 
were done with Newcastle Ottawa Scale for Cohort studies and with CEBM for Randomized Controlled Trial 
Studies. Risk of bias assessed using Cochrane Method. A total of 7 studies were included in the final review 
with 1 RCT and 6 Cohort study. Most study have no significance in overall survival, progressive disease or 
distant metastasis free time, but differ in high stage and high risk patient. Three studies included toxicity as an 
outcome with adjuvant toxicity outweigh the need to add another round of chemotherapy. 
Conclusion: Adjuvant chemotherapy is believed to be necessary in eliminating residual cancer cells but current 
studies shows little improvement in overall survival and sometimes unbearable toxicities. 
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1.1 Nasopharyngeal Carcinoma Epidemiology 
Nasopharyngeal cancer (NPC) incidence in Indonesia are higher than 
Global incidence by 3 times. From data published by GLOBOCAN in 2012 
there are 87.000 new cases [1]. Indonesia’s are among the top 5 countries 
with highest prevalence of NPC with a meta analysis from 2018 stating 
prevalence as high as 13.084 cases. This number were obtained without 
national cancer registry [2]. A study from RS Hasan Sadikin Bandung 
conducted from 2010-2014 show there are 692 NPC cases, another study 
from H. Adam Malik Hospital in Medan number of cases in 2011 reach 103 
cases per year, study from Dharmais Cancer Hospital in Jakarta up to 136 
with a more complicated treatment and poor prognosis. 
1.2 Treatment Guideline for Nasopharyngeal Carcinoma 
According to the latest guideline published by National Comprehensive 
Cancer Network(NCCN) in 2018 [6]. The main treatment for NPC remain 
radiotherapy, chemotherapy, and surgery. As radiotherapy were proven to be 
effective for NPC, surgery indication are remain on those with persistent, 
recurrent or those refusing treatment using radiation or chemotherapy drugs. 
The main pattern consistent with this guideline is that systemic therapy are 
widely used for various stages and with different techniques.  
1.3 Systemic Treatment for Nasopharyngeal Carcinoma 
Drug that are used the most are the platinum based such as carboplatin and 
cisplatin [7]. Drugs such as 5-flourouracil, taxanes (paclitaxel or docetaxel), or 
gemcitabine are used as subtitute or addition. Other drugs are being developed 
including molecular-targeted therapy, it works by blocking the epithelial growth 
factor receptor (EGFR) signalling pathway [8]. Guideline for NPC in children 
and adolescent are using interferon B as treatment in high risk patient of stage 
II,III, and IV [9]. While because of the connection with Epstein-Barr viruses, 
vaccination to activate cytotoxic cells are being evaluated [8].  
1.3.1 Principle of Chemotherapy 
Principles in giving chemotherapy including knowing the chemotherapy agents 
used, efficacy and toxicity related to the drugs, clinical use of the chemotherapy, drug 
resistance and administration of the drugs. In table 1 are the list of mechanism and their 
associated drug. In administering chemotherapy drug, physicians needs to think about 
the delivery of the drug to cells and activation/deactivation of drugs, and patients 
response, their performance status, quality of life and the overall survival needs to be 
evaluated and taken into consideration [10]. Routes of administration include oral, IV 
injection, infusion, and intrathecal [10].  
1.3.2 Current Role of Chemotherapy in NPC 
From various study and meta-analysis conducted, concurrent 
chemoradiation (CCRT) increased the survival benefit in 5 years, in figure 2 
are phase III trial of CRT compared to radiotherapy only.  In this study, overall 
survival was not significantly different but improvement were seen on failure 
free survival taken at 3-year and 5-year follow up [11]. Hence, it has become 
a standard to treat with CCRT. Induction or adjuvant chemotherapy place in 
treatment are still uncertain because variety of results from multiple clinical 
trial. Induction chemotherapy are used to help down-stage locally advance 
tumours and to control micro metastases and their toxicities.  
1.4 Antineoplastic drug in Nasopharyngeal Carcinoma          
Chemotherapy 
 
1.4.1 Platinum-based (Cisplatin and Carboplatin)  
Platinum-based drug, mainly cisplatin, were used as chemotherapy in NPC 
treatment. Figure 3 describe the cytotoxicity mechanism of this drug. It is infused 
intravenously although it is the most widely used, its toxicity is higher than 
carboplatin. It includes hepatic dysfunction, nephrotoxicity, ototoxicity, peripheral 
neuropathy, nausea, vomiting and myelosupression. Its usage are combined with 
other drugs to lessen drug resistance and manage its adverse effects. Chemotherapy 
are usually given in 3-4 weeks interval.[12] 









Picture 1. Cytotoxicity of Cisplatin 
1.4.2 5-Flourouracil (5-FU) 
This drug works by covalently bounding to enzyme and the results are 
decreased folate and thymine, it inhibits DNA and RNA and causes failure 
of synthesis and functioning. Due to its short half-life, it is given through 
continuous infusion and very highly schedule dependent. It toxicity include 
myelosuppression, gastrointestinal toxicity, mucositis, skin toxicity (hand 
and foot syndrome), and neurotoxicity [12]. 
2. MAIN TEXT 
NPC are prevalent in Indonesia and the treatment are multidisciplinary 
and have a big effects to patients, their family, and the community. Additional 
dosages means increased possibility to toxicity and longer treatment time. 
Adjuvant chemotherapy were given because patient have relapse at distant 
sites after concurrent chemotherapy only. But, patients are less likely to follow 
through and the adverse effect may hinder these patient from completing the 
treatment. This systematic review are conducted to see the outcome of 
adjuvant therapy compared to concurrent chemoradiation only.  
2.1 Study Selection  
Study type included are cohort, clinical random trial, and case control 
study in NPC patient all stages with available follow up data including 
survival and toxicity within the last 5 years. Studies excluded are those not 
comparing concurrent with adjuvant chemotherapy as sub-study or main 
study analysis. Less than 10 participants in studies. If more than 50% of 
participants dropped out. 
Type of participants included are adult and children with NPC already 
undergoing work up and staging. The staging is further categorized as early and 
advanced. Early defined as AJCC NPC stadium I and II. Advanced defined as 
AJCC NPC stadium III and IV. Patient completed the treatment cycle. While 
those excluded are patients receiving CRT and CT as palliative treatment. 
Type of interventions included are all studies using platinum-based 
chemotherapy all dosages; and excluded if more than 50% of participants 
didn’t complete the intervention and added treatment for NPC other than 
chemoradiotherapy (eg. Targeted therapy). 
In the study, there is type of outcome which divided into: 1) All type of 
outcome are included in the study preferred outcome are survival (overall 
survival, disease free survival, or locoregional survival), toxicity, and 
quality of life; 2) overall survival are measured at the time of treatment for 
a certain amount of time. In this study minimum of 2 years were included; 
3) disease free survival are defined as the length of time from primary 
treatment to the ends of patient survive without any symptoms of the 
disease; 4) toxicity grade are based on the Common Terminology Criteria 
for adverse events (CTCAE) or adverse effect short or long term. 
2.2 Search Strategy  
2.2.1 Electronic search 
The search on 2 May 2019 was performed by the author using online 
databases are included in Pubmed and Central. The detail of keywords used 
will be presented in Table 1. Limitation of studies included are articles in 
English, and in humans. Afterwards, the study title and abstracts were 
screened for related articles.  
 
Table 1. Search strategy 
 Search terms 
Pubmed  ((((((nasopharyngeal) OR nasopharynx)) AND (((carcinoma) OR cancer) OR 
malignancy)) AND concurrent) AND ((adjuvant) OR addition)) AND 
(((outcome) OR toxicity) OR survival) 
CENTRAL 
Cochrane 
(nasopharyngeal carcinoma):ti,ab,kw AND (adjuvant chemotherapy):ti,ab,kw 
AND((concurrent chemotherapy):ti,ab,kw OR (CRT):ti,ab,kw OR 
(chemoradiotherapy):ti,ab,kw) AND ((outcome):ti,ab,kw OR 
(survival):ti,ab,kw OR (toxicity):ti,ab,kw) 
2.3 Assessment of Study  
2.3.1 Assessment of eligibility  
Assessment was done by the author using exclusion and inclusion 
criteria discussed above. 
2.3.2 Assessment of methodological quality and risk of bias 
Assessment will be done by the writer using two tools from cochrane 
study handbook. First NOS (Newcastle Ottawa Scale) for cohort and case 
control studies and NRT according to Cochrane. Second toold are Risk of 
Bias of Cochrane for quality assessment for RCT. Tools available from 
Cochrane study handbook. 
2.3.3 Data Extraction   
Data extracted from the studies are study author, year of publishing, 
location of trial, number of participants, characteristic of patients, 
chemotherapy regiment used, and outcome of studies (overall survival, side 
effects, disease free rate and p-value) 
3. RESULTS 
3.1 Search studies  
Using the term in table 1, with inclusion stated previously, total of 179 
(129 Pubmed 50 Cochrane) articles were found.  Further selection can be 
seen in Picture 2.  
Picture 2. Search studies 
3.2 Description of studies 
Six study were cohort study and one randomized controlled trial. All 
studies included platinum based chemotherapy with or without combination 
with other chemotherapeutic agents. Most study were conducted in Chine 
but 1 which was conducted in Japan. The studies involved NPC patient 
ranging from 15-70. 
3.3 Comparisons  
Six articles are assessed using Newcastle Ottawa Scale(NOS). All 
studies were considered high quality. One RCT study were assessed using 
CEBM, with good validity.  
3.4 Outcomes  
All  studies included overall survival as outcome, with 3 study also 
included toxicity. Other that overall survival these studies also included 







Progression Free Survival(PFS), Distant Metastasis Free Survival (DMFS), 
Failure Free Survival (FFS) and Locoregional Free Survival (LFS) 
3.5 Effects of intervention  
Two out of 7 study, that routine use of AC should only be considered in 
patient with high nodal stage or high risk according to independent 
prognostic factor which is albumin level, T and N stage, and age. One RCT 
propose other prognostic method such as EBV level post therapy should be 
use for decision making.  One study conclude that it shouldn’t be used unless 
the tumors are considered persistent or in recurrence cases. Three other 
study did not agree with routine usage of AC considering they have no 
survival benefit. 
4. DISCUSSIONS 
Most of the study conducted are located in China where NPC incidence 
remains high at 3/100.000 population (twice the world incidence) with 
patient never undergoing treatments except Yang et al whose subject are 
those with residual carcinoma. Chen L et al mentioned EBV DNA load post 
treatment as one of the factors to guide AC usage, with results from another 
study showing those with higher EBV DNA post-therapy are more likely to 
be resistant to platinum-based chemotherapy therefore giving adjuvant 
chemotherapy doing more harm than good [11]. High risk patient mentioned 
in Liang ZG et all are those with age>45 years, T3-4, N2-3, and albumin 
≤42 g/L.With toxicity as main concern for platinum-based chemotherapy 
usage, other chemotherapy agent are mentioned in Zhang et al who uses S-
1 containing tegafur and gimeracil in N3 stage NPC patient with reported 
toxicities grade 1 and 2 [13]. Tegafur are a prodrug form of 5-flourouracil 
and gimeracil itself enhances flouropyrimidines by inhibiting its 
degradation allowing lower dose to be used and reducing its side effect [14]. 
Other drug with proven satisfactory result are capecitabine and tegafur-
uracil [15]. 
5. CONCLUSION 
Although it has shown trend towards improvement in OS, but it is not 
statistically significant, especially considering the toxicity. Platinum-based 
adjuvant chemotherapy may be used on patient with advanced stage NPC 
who have positive predictor to benefit from the extra dose of chemotherapy. 
Newer drug showing promising result with less toxicity reported needs to 
be explored as alternative.  
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Bias Concurrent Radiotherapy Adjuvant 
Chen L et al, 
2016 
RCT China 477 Age 18-70 with type II/III 
WHO, advanced  stage 
except T3-4N0 
Cisplatin 40 mg/m2 66 Gy or greater in main 
area and 60 – 66 Gy in 
surrounding area 
 cisplatin 80mg/m2 day 1 
 5-FU 800 mg/m2 day 1-5 












Cohort  Japan 31 Median age 55 with 
advanced stage, mostly type 
II and III  histology (84%) 
Docitaxel 5-10 mg/m2 
Cisplatin 20 mg/m2 
Once weekly, same day 6 
cycles 
Conventional technique 






 Docitaxel 60 mg/m2 
 Cisplatin (60 mg/m2) 
 5-FU (600 mg/m2/day for 5 days 
OR 
 Cisplatin  (100mg/m2) 
 5-FU 1000mg/m2/day for 5 days 
OR 
 Docitaxel ( 60 mg/m2   
 Carboplatin  
 Penendoscopy every 2 months for 3 years and 6 
months the next 3 years 
 Neck CT scan and chest Xray every 6 month first 
3 years and annualy per year after 
 Until death or data censoring 




High  +++ 
Liang ZG et 
al, 2016 
Cohort  China 511 Mostly male Cisplatin alone every 3 
weeks for 2-3 cycles 
54-74 Gy delivered in 
30-32 fraction, 5 fraction 
per week over 6-7 weeks. 
Platinum based with 2/3 
drugs(docetaxel and/or 5FU) every 4 
weeks for 2-3 cycles 
Every 3 months for 2 years and every 6 months 3 
years after, then yearly. Examination consist of 
physical examination, US scan of abdomen, Chest 
X-ray, CT scan or MRI, Bone scan, 





High  +++ 
Zhong Q et al, 
2016 
Cohort China  522 Patient from 16-75 without 
prior management using 
chemotherapy or 
radiotherapy no metastasis 
and WHO type II or III 
histopathology. 
1 to 3 cycles of cisplatin 
alone 100 mg/m2 every 3 
weeks 
IMRT 60-71 Gy 5 
fractions per week for 6-
7 week.   
1 or 3 cycles of cisplatin 80 mg/m2 on 
dary 1 to day 3  
5 FU 750 mg/m2 day on day 1-5 every 
3 weeks.  
 Assessed every 3 months for 2 years, 6 months in 
year 3-4. 
 Follow up examination include body check, blood 
count, liver and kidney functuion, CT scan 
thorax, abdominal USG, MRI of nasopharyngeal 





High  ++ 
Yang S et al, 
2015 
Cohort  China  155 Patients with stage IVB who 
had local residual lesions 
after the first course of 
cisplatin-based CCRT with 
our without AC 
Cisplatin 100 mg/m2/day 
per 3 weeks 
2DRT or 3DCRT 
68 or greater Gy 
 Cisplatin/ nedaplatin 80 mg/m2 on 
day 1  
 5-FU 800 mg/m2 day 1-5 every 3-4 
weeks. 
 Months interval for the first 2 years, every 6 
months year 3-5 and yearly after.  
 Assessed by fiberoptic endoscopy and biopsy, 
MRI, clinical symptom, physical examination, 





High  +++ 
Dong Y et al, 
2015 
Cohort  China  488 Patients with stage III and 
IVa-b  with normal renal and 
hepatic function, normal 
complete blood count, 
absence of severe cardiac 
disease, and no previous 
radiotherapy or 
chemotherapy 
 Cisplatin 27 
mg/m2/day on day 1-3 
 5-FU 800 mg/m2/day 
on day 1-5 
OR 
 Cisplatin 27 
mg/m2/day on day 1-3 
 paclitaxel 135 mg/m2 
on day 1 every 4 weeks 
for 3 cycle 
2DRT or 3DCRT  66-70 
Gy on nasopharynx, 60-
66 Gy on neck. 5 
fractions per week 
One month after CCRT completion. 
 Cisplatin 27 mg/m2/day on day 1-3 
 5-FU 800 mg/m2/day on day 1-5 
OR 
 Cisplatin 27 mg/m2/day on day 1-3 
 - paclitaxel 135 mg/m2 on day 1 
every 3 weeks for 3 cycle 
 Assessed every 3 months for 2 years, 6 months 
in year 3-4.  
 Recurrences diagnosed by endoscopic biopsi/ 
MRI/ intensive CT 






- Acute and Late 
toxicity 
High  ++ 
Liang Z et al, 
2014 
Cohort  China 260 Patient age 13-70, no 
metastasis, with Karnofky 
scores ≥ 70 
Cisplatin 75-100 mg/m2 
day 1-3 every 3 weeks 
OR 
Cisplatin 80 mg/m2 on 
day 1-3 + 5FU 1000 
mg/m2 daily on day 1-5 
OR 
1 or 2 cycles of cisplatin 
alone plus 1 or 2 cycles 
of cisplatin – 5FU 
2DRT : 68-78 Gy 
cummulative doses in 5 
fractions/week 
OR 
IMRT : 66-74 Gy for 30-
32 fractions at 5 fraction 
per week.  
Cisplatin 75-100 mg/m2 day 1-3 every 
3 weeks 
OR 
Cisplatin 80 mg/m2 on day 1-3 + 5FU 
1000 mg/m2 daily on day 1-5 
OR 
1 or 2 cycles of cisplatin alone plus 1 
or 2 cycles of cisplatin – 5FU 
Every 3 months for 2 years and every 6 months 3 
years after, then yearly. Examination consist of 
physical examination, US scan of abdomen, Chest 
X-ray, CT scan or MRI, Bone scan, 











International Journal of Nasopharyngeal Carcinoma (IJNPC) Vol. 02, No. 03, September 2020 | 74-78 
 
 




OS PFS FFS DFFS LRFS 
Chen L et al, 
2016 
Did not differ significantly  N/A Did not differ 
significantly 
Did not differ 
significantly 
Did not differ 
significantly 
Did not differ significantly, but 
incidence of peripheral neuropathy 
higher in AC group. 
Considering compliance and toxicity of AC, routine delivery of AC after 
CCRT should be reconsidered for patients with advanced stage NPC and not 
considered only by TNM staging. 
Nakahara et al, 
2016 
Did not differ significantly Did not differ 
significantly 
N/A N/A N/A Higher level of grade 4 hematologic 
acute toxicities in AC patients.  
AC should only be considered only for patients with clearly evident 
persistent or recurrent disease. 
Liang ZG et al, 
2016 
Significant difference in high risk patients (high risk 
predictor : age>45 years, T3-4, N2-3, and albumin 
≤42 g/L) and advanced T stage (T3-4) 
N/A Did not differ 
significantly 
Did not differ 
significantly 
Did not differ 
significantly 
N/A High risk patient with locoregionally advanced NPC may gain survival 
benefit from the addition of AC.  
Zhong Q et al, 
2016 
1-,2-,3- year survival in high stage patient (III and 
IV) statistically significant. 
N/A N/A Did not differ 
significantly 
Did not differ 
significantly  
 
N/A Those with locally advanced might benefit from adjuvant 
Yang S et al, 
2015 
Did not differ significantly N/A Did not differ 
significantly 
Did not differ 
significantly 
Did not differ 
significantly 
N/A Although patient given adjuvant therapy show improvement it was not 
significant compared with CCRT only, there for it should not be used 
routinely except for clinical trial. 
Dong Y et al, 
2015 
Did not differ significantly Did not differ 
significantly 
N/A Did not differ 
significantly 
Did not differ 
significantly 
Adverse event ≥grade 3 higher in AC 
group as well as late toxicities  
Addition of AC increases toxicity with no significant survival benefit in 
locoregionallly advanced carcinoma. 
Liang Z et al, 
2014 
Borderline significant difference in patient with N2-
3 
N/A Did not differ 
significantly 
Did not differ 
significantly 
Did not differ 
significantly 
N/A Although the result show borderline significant result in advanced nodal 
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